Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11008466 | International Journal of Antimicrobial Agents | 2018 | 16 Pages |
Abstract
This article reports a pharmacokinetic case study of intravenous posaconazole in a 49-year-old male patient with intra-abdominal sepsis and hypoalbuminaemia receiving continuous venovenous haemodiafiltration. Concentration-time data following 300 mg intravenous posaconazole was analysed using a population pharmacokinetics approach. The 300-mg intravenous dose appears to be adequate for the treatment of yeast infections; however, for the treatment of invasive aspergillosis in isolated cases of critically ill patients with hypoalbuminaemia, the current dosing may not achieve desired exposure, although steady state exposure data are needed.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Fekade B. Sime, Janine Stuart, Jenie Butler, Therese Starr, Steven C. Wallis, Saurabh Pandey, Jeffrey Lipman, Jason A. Roberts,